Skip to Content
scroll

Clinuvel Pharmaceuticals (CUV)

ASX.CUV $15.39

20 MINUTE DELAYED

14 DAYS FREE ACCESS

Join Market Matters and get full access
to all our Opinion + Action

LEARN MORE

CUV $15.39

20 MINUTE DELAYED

TODAY

-0.39 %

1 YEAR RETURN

0.00%

VOLUME

34,804

DIV YIELD

0.32%

PE RATIO

25.33

52 WEEK RANGE

12.96

21.45

ANALYSIS

i

SHARE PRICE ACTIVITY
Last (Price)

15.39

Change

-0.06 (-0.39)

Bid / Ask

15.17 - 15.50

Volume

34,804

Turnover

533,343

Open

15.46

Day Range

15.12 - 15.49

VWAP

15.32

Prev Close

15.45

Last Trade

20/05 4:10pm (AEST)

i

KEY INFORMATION
Sector

Healthcare

Shares Issued

39,859,990

NTA/Share

0.00

Last Dividend

0.05

Dividend Ex Date

05 SEP 2023

Dividend Pay Date

20 SEP 2023

i

BROKER CALLS

current

Mean

0.00

Target Price

0.00

i

CURRENT ()
Revenue

EBITDA

Profit

Earnings Per Share (EPS)

0

Dividend Per Share (DPS)

0

Yield %

0.32

Market Cap

0

Price to Earnings Ratio (P/E)

25.33

i

TARGET PRICE FORECAST

i

ESTIMATES ()
Revenue

0.00

EBITDA

0.00

Profit

0.00

Earnings Per Share (EPS)

0.00

Dividend Per Share (DPS)

0.00

i

BROKER CONSENSUS RECOMMENDATION

BUY

SELL

Target Price

0.00

Lt Growth Rate

0.00

Recommendation ()

0.00
OPINION
ACTION
image description

Business Summary

Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. Its principal activity consists of commercializing and distribution in Europe and the United States, Israel, and Australia of its drug candidate SCENESSE for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pipeline includes PRENUMBRA, NEURACTHEL, CUV9900, and Parvysmelanotide (VLRX001). PRENUMBRA is a liquid (non-solid) injectable formulation of afamelanotide designed to provide a flexible dose of afamelanotide, a synthetic analogue of natural α-melanocyte stimulating hormone. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH), for neurological, endocrinological and degenerative disorders.

image description

Only available to Members

Take a free 14 day Market Matters trial – full access to all our reports, portfolios, positions, buy and sell recommendations. Access the latest views on the latest developments from professional money managers. It's free and no payment details are required
For membership options and pricing. Click here
Back to top